Patient P-01422

Synthetic patientNBL-101 · Day 109 · 65–74 · M · baseline S16Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Favorable

Inflammatory state

Favorable

Nutritional resilience

Favorable

Discontinuation risk

11%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S16

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days

Toxicity+6
GI instability-2

What helped?

No interventions yet.

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

17.2/100

improving · -1.9 vs previous 14 d

Toxicity

Blood

16.3/100

worsening · +2.9 vs previous 14 d

Sleep quality

Wearable

65.5/100

stable · +2.3 vs previous 14 d

Energy level

Daily log

7.5/10

stable · +0.1 vs previous 14 d

Stress level

Daily log

4.3/10

stable · -0.1 vs previous 14 d

Steps

Wearable

5,905

stable · -40 vs previous 14 d

Adherence

Companion

94.2 %

stable · +1.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 89 from the failing basin, 2 from restoration.

Would help

No untried action with strong evidence. Compose one from primitives.

Would not help

Keep histamine low
GI +3.3 next day on high-intake days · n 16

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+3.3detractor · 95%
Simple carbohydrates
+0.8no signal · 36%
Dietary fat load
-0.6no signal · 18%
Insoluble fibre
-0.4no signal · 15%
Alcohol
+0.4no signal · 15%
Spicy / capsaicin
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 4.3 · butyrate capacity 58/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 61 ms
Sleep: 8.1 h
Steps: 5,590
Resting HR: 63 bpm

Daily log: GI score 17, nutritional resilience 66, adherence 94.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01439	48%	S18	ME-01	improved	79
P-01467	48%	S09	HY-01	improved	79
P-01625	46%	S06	SC-12	improved	83
P-01329	45%	S08	BR-03	improved	79
P-01671	44%	S04	SC-12	improved	90
P-01796	42%	S09	SC-12	improved	86
P-01798	41%	S08	NP-02	improved	78
P-01479	40%	S15	DT-01	improved	84
P-01855	40%	S04	DT-01	improved	73
P-01495	39%	S07	BR-03	improved	85
P-01654	39%	S08	CR-01	improved	85
P-01791	39%	S06	ME-01	improved	79